Apexigen, Inc. | Press Releases

Date	Title	View
September 10, 2022	Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
September 7, 2022	Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022	Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
August 4, 2022	Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
August 1, 2022	Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
July 18, 2022	Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination
July 11, 2022	Apexigen to Participate in the Brookline Capital Markets Newport Symposium
June 29, 2022	Apexigen Announces Board Appointment and New Chair
June 8, 2022	Apexigen Appoints William Duke as Chief Financial Officer
June 6, 2022	Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy